HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ara A. Vaporciyan David Rice Garrett Walsh Stephen Swisher Jack Roth Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaporciyan, A. A. Articles by Roth, J. Search for Related Content PubMed PubMed Citation Articles by Vaporciyan, A. A. Articles by Roth, J. Related Collections Cardiac - other Mechanical Circulatory Assistance

Eur J Cardiothorac Surg 2002;22:47-52
© 2002 Elsevier Science NL

Resection of advanced thoracic malignancies requiring cardiopulmonary bypass

The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77025, USA

Received 19 September 2001; received in revised form 20 March 2002; accepted 25 March 2002.

* Corresponding author. Tel.: +1-713-745-4547; fax: +1-713-790-4901
e-mail: avaporci{at}notes.mdacc.tmc.edu

Objectives: Patients with malignancies involving cardiac structures have limited therapeutic options and significant risk of mortality. The decision to offer radical palliative or curative resection must be made only after consideration of the substantial surgical risks. The purpose of this retrospective study was to determine the feasibility and benefits of resection with cardiopulmonary bypass (CPB) of metastatic or non-cardiac primary malignancies extending directly into or metastasizing to the heart in select patients. Our results were examined to assess the risks and benefits of such radical therapy. Methods: We retrospectively reviewed patient charts and identified all patients with malignancies involving the cardiac chamber or great vessels (excluding renal carcinomas with caval extension) or with substantial cardiac compression who had undergone resection with CPB at The University of Texas M.D. Anderson Cancer Center between January 1995 and July 2000. We evaluated demographic data, symptomatology, tumor characteristics, and outcomes. Results: Nineteen patients (six males and 13 females; median age of patients, 47 years; age range, 17–67 years) were included in the study. Eleven patients underwent surgery with curative intent, and eight underwent surgery with palliative intent. Seventeen patients had tumors that required CPB because their tumors directly involved the heart and/or great vessels (nine sarcomas, seven epithelial carcinomas, and one unclassified), and two patients (both with sarcomas) required CPB to relieve tumor tamponade. The technique included CPB (n=5), CPB with diastolic arrest (n=12), and CPB with hypothermic circulatory arrest (n=2). Five patients underwent concomitant pneumonectomy, and three underwent lobectomy. Two patients (11%) died in the hospital after resection with palliative intent. Of the 11 patients who underwent resection with curative intent, ten (91%) had complete resections. The median time in the intensive care unit was 5.3 days (range, 0–37 days) and the median length of hospital stay was 17.2 days (range, 0–107 days). Major complications occurred in 11 patients (58%); the most common major complications were pneumonia (n=7 patients), mediastinal hematoma (n=4 patients), and acute respiratory distress syndrome (n=2 patients). The median follow-up duration was 27 months. The overall 1- and 2-year survival rates were 65 and 45%, respectively. Conclusions: Extensive thoracic tumors involving cardiac structures can be resected with acceptable risk. When resection was performed with curative intent, excellent 1- and 2-year cumulative survival rates were achieved. Although resection with palliative intent was associated with greater mortality rates, some patients survived for 1 and 2 years. The use of CPB in selected patients with thoracic malignancies should be considered, especially when complete resection can be achieved.

Key Words: Metastasis • Cardiac tumors • Cardiopulmonary bypass

This article has been cited by other articles:

				K. Wiebe, H. Baraki, P. Macchiarini, and A. Haverich Extended pulmonary resections of advanced thoracic malignancies with support of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 571 - 577. [Abstract] [Full Text] [PDF]

				W. Weder Editorial comment Extended pulmonary resections of advanced thoracic malignancies with support of cardio-pulmonary bypass - is surgery justified? Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 577 - 578. [Full Text] [PDF]

				M. de Perrot, E. Fadel, S. Mussot, A. de Palma, A. Chapelier, and P. Dartevelle Resection of Locally Advanced (T4) Non-Small Cell Lung Cancer With Cardiopulmonary Bypass Ann. Thorac. Surg., May 1, 2005; 79(5): 1691 - 1696. [Abstract] [Full Text] [PDF]

				K. Asai, K. Suzuki, H. Shimota, T. Takahashi, K. Yamashita, and T. Kazui Malignant peripheral nerve sheath tumor of the mediastinum: A temporary aortic transection approach J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 615 - 617. [Full Text] [PDF]